{"entity":{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Farletuzumab-exatecan in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","summary":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07744763 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 260 participants planned, started 2025-03-28 and due to reach its primary completion in 2027-03-28. Interventions recorded: SYS6041.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07744763","url":"https://clinicaltrials.gov/study/NCT07744763"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["farletuzumab-exatecan"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07744763","phase":"1/2","setting":"A Multicenter, Open-label, Dose-escalation and Dose-expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Antitumor Activity of SYS6041 in Patients With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":260,"outcomes":[]},"route":"/trials/nct07744763/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}